Analysts/Institutional Investor Meet/Con. Call Updates

November 03, 2026 The Manager (CRD) The Manager –Listing Department The BSE Limited National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Fort, Bandra-Kurla Complex, Bandra (East) Mumbai- 400001 Mumbai - 400 051 Scrip Code: 530117 Symbol: PRIVISCL Dear Sir / Madam, Ref: Letter dated October 30, 2026, providing Audio link of the Analyst / Investors Meet Sub: Transcript of Analyst/ Investors Meet held on Friday, October 30, 2026 In addition to Audio Link shared via letter dated October 30, 2026, please also find enclosed the transcript of the Analysts/Investors Call on the Un-audited Standalone and Consolidated Financial Results of Privi Speciality Chemicals Limited for the quarter and half year ended September 30, 2026, held on October 30,2026. You are requested to kindly take the same on record. Thanking you. Yours Sincerely, For Privi Speciality Chemicals Limited Ashwini Saumil Shah Company Secretary Encl: As above Privi Speciality Chemicals Limited Q2 & H1 FY27 Earnings Conference Call October 30, 2026 MANAGEMENT: MR. MAHESH BABANI – CHAIRMAN AND MANAGING DIRECTOR – PRIVI SPECIALITY CHEMICALS LIMITED MR. R.S. RAJAN – PRESIDENT – PRIVI SPECIALITY CHEMICALS LIMITED MR. NARAYAN S. IYER – CHIEF FINANCIAL OFFICER – PRIVI SPECIALITY CHEMICALS LIMITED MR. SANJEEV PATIL – EXECUTIVE VICE PRESIDENT, STRATEGY AND BIOTECHNOLOGY – PRIVI SPECIALITY CHEMICALS LIMITED MS. ASHWINI SHAH – COMPANY SECRETARY AND COMPLIANCE OFFICER – PRIVI SPECIALITY CHEMICALS LIMITED Page 1 of 14 Privi Speciality Chemicals Limited October 30, 2026 Moderator: Ladies and gentlemen, good day, and welcome to Privi Speciality Chemicals Limited Q2 and H1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. From the management, we have with us Mr. Mahesh Babani, Chairman and Managing Director of the company; Mr. R.S. Rajan, President of the company; Mr. Narayan S. Iyer, Chief Financial Officer of the company; Mr. Sanjeev Patil, Executive Vice President, Strategy and Biotechnology; Ms. Ashwini Shah, Company Secretary and Compliance Officer. And before we begin the conference call, I would like to mention that some of the statements made during the course of today's conference call may contain forward-looking statements about the company, which are based on beliefs, opinions and expectations of the company as on date of this call. These statements are not the guarantees of future performance and may involve risks and uncertainties that are difficult to predict. I would now like to hand the conference over to Mr. Mahesh Babani, Chairman and Managing Director of Privi Speciality Chemicals. Thank you, and over to you, sir. Mahesh Babani: Thank you, ma'am. Good evening, everyone. This is Mahesh Babani. Thank you for joining Privi Speciality Chemicals Q2 H1 '27 Earnings Conference Call. I'm pleased to share that we have delivered our strongest ever quarterly performance, notwithstanding very adverse global headwinds. We have achieved our highest ever sales and profitability. At the same time, we have been continuing to build capabilities which will support the next phase of our growth. The performance reflects the strength of our underlying business, the relationships we have built with our customers and the investments we have made in our manufacturing capabilities. Over the past few years, our focus has been building a broader, more resilient and more differentiated specialty aroma chemical business. Reflecting our confidence in the business and our commitment to creating value for shareholders, the Board has declared the company's first ever interim dividend of INR5 per share of face value INR10 for the financial year '26-'27. We remain encouraged by the opportunities ahead while staying focused on disciplined execution. With that, I would like to invite my team, Mr. Rajan, Sanjeev and Narayan, to discuss our operational development and the progress we are making across our expansion and product initiatives. Thank you. Sanjeev Patil: Thank you. This is Sanjeev Patil. Good afternoon to all the listeners and investors. As Mahesh bhai mentioned, we have achieved our highest ever quarterly total revenue of INR773 crores and EBITDA of INR212 crores. This performance has been delivered against a global backdrop Page 2 of 14 Privi Speciality Chemicals Limited October 30, 2026 shaped by geopolitical uncertainty, changing trade flows and volatility in the input and logistic cost. At the same time, customers continue to place strong emphasis on dependable supply and consistent quality. For a global specialty aroma chemical supplier like Privi these conditions reinforce the importance of operation reliability, diversified sourcing and process efficiency and close partnership. During Q2 and H1 of '27 our operational priorities remained firmly focused on preparing Privi for its next stage of growth. This involves adding capacity in a major manner, ensuring operational readiness, strengthening our product portfolio and building the capabilities required to scale efficiencies. Our Phase 1 program is designed to increase install capacity from 48,000 metric tons per annum to 54,000 metric tons per annum, representing an addition of 6,000 metric tons per annum. As of 30th September 2026, this project has been completed. We are on course for implementing maltol, ethyl maltol, ethyl vanillate, that is Musty, and cyclopentanone along with other molecules planned as part of subsequent phases of expansion. Moving products through development, sampling, customer qualification, and commercialization takes time. Each successful transition has the potential to broaden our portfolio and deepen our engagement with customers. At PRIGIV, our joint venture with Jeevadan, we remain focused on scaling the existing business and building a stronger portfolio of higher value products. The joint venture had achieved its first profitable quarter in Q4 FY26, and indeed in Q2 FY27, PRIGIV has made profit. Our focus is now on building scale, improving consistency, and supporting its continued development. Alongside these growth initiatives, we continue to prioritize reliable supply, disciplined raw material sourcing, process efficiency, and operational excellence. These capabilities are particularly important in an environment where feedstock prices, logistic cost, and geopolitical developments can change very quickly. By strengthening these fundamentals, we aim to maintain service reliability and customer confidence while continuing to invest in future growth. To summarize, we are on track towards our 5K 1K plus vision. With that, I will hand over to Mr. Narayan Iyer, our CFO, to take you through our financial performance. Thank you. Narayan S. Iyer: Good evening to everyone of you, and thank you, Mahesh bhai, and thank you, Sanjeev, for the insights. And a warm welcome to all my investors in this Privi Speciality Chemicals Limited quarter 2 earnings call. I'm Narayan S. Iyer, the Chief Financial Officer, and I would like to give certain highlights with regard to the financial performance. I'm pleased to report that quarter 2 for financial year '26-'27 was a record quarter in terms of both sales and profitability. This is an important milestone and reflects the strong operating momentum of our business and our company. Quarter 2 in financial year '26-'27 extended our strong operating momentum with a total income of INR773.16 crores, up 13.9% year-on-year and EBITDA achieved was INR212.49 crores, up 16.66% and a profit after tax of INR117.03 crores, reflecting a 24.61% growth over the previous year. Page 3 of 14 Privi Speciality Chemicals Limited Octo [Showing first 8,000 characters — download PDF for full document]